Biovica and IBL America has agreed on a sales collaboration for the US market
Uppsala, Sweden, April 10, 2019: Biovica has agreed on a collaboration with IBL-America for sales of DiviTum® for the research market in the US. The partnership will further increase the commercial activities for this customer segment on the single largest market for Biovica.
The agreement gives IBL-America non-exclusive rights to sell DiviTum® to pharmaceutical companies, Contract Research Organizations and research institutes in the US.The collaboration will further increase the commercial activities for this customer segment in the US, which is the single largest market for Biovica.
DiviTum® has great potential within many commercial areas. For the research market, it is useful tool for the pharmaceutical and biotech industry for evaluating cell-cycle regulating compounds, CDK inhibitors and endocrine drugs and can be used all the way from cell culture studies to clinical trials for drug approval.
“DiviTum® will give us an excellent opportunity to generate value for our customers. We look forward to working with Biovica and to expand our product portfolio within the oncology research product line”, says Mark Kowal, President/CEO, IBL-America.
“Besides Biovica’s on-going commercialization initiative for the clinical breast cancer market, we also wish to contribute to the development of new improved oncology drugs. Biovica already have customers in the US research market and on-going collaborations with prominent research institutes. The partnership with IBL-America will create excellent opportunities to grow the customer base for the research market in the US”, says Anders Rylander, CEO Biovica.
“We are excited to work with IBL-America, a company with long experience of distributing high quality laboratory research products in the US. IBL-America will become an important partner to increase our presence for the important US research market”, says Pontus Nobréus, Business Development Director Biovica.
About IBL-America For over 20 years, IBL-America has provided high-quality laboratory reagent assays, antibodies and proteins for research and clinical testing in various areas including, but not limited to, autoimmunity, endocrinology, infectious disease, oncology and neuroscience. IBL-America also has the capability to provide technical support with our experienced technical team and their modern, fully-equipped internal laboratory.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
This cookie is installed by Google Analytics.
A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
Hotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
Hotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.